Close menu




February 1st, 2022 | 10:38 CET

BYD, BrainChip, Daimler: The chip strategy decides

  • Technology
Photo credits: pixabay.com

As Handelsblatt recently wrote, the automotive industry is still suffering from a chip shortage. As the leading media reports, according to the European Union, around 11.3 million new cars could not roll off the production line due to supply difficulties. Europe now wants to counter this with its own chip strategy. We highlight three stocks and explain who can profit.

time to read: 3 minutes | Author: Nico Popp
ISIN: BYD CO. LTD H YC 1 | CNE100000296 , BRAINCHIP HOLDINGS LTD | AU000000BRN8 , DAIMLER AG NA O.N. | DE0007100000

Table of contents:


    BYD: Why the Chinese are well positioned

    Apart from Bosch, no other company has built a chip factory in Germany in the past 15 years - no wonder Chinese automakers are rubbing their hands in the face of the shortage. Although China is also a minor player in the international production of semiconductors compared to Taiwan and South Korea, the situation in the Middle Kingdom is at least better than in Europe: China produces 16% of the world's chips, Europe 9%. Chinese carmaker BYD is also getting into the act. The Company manufactures cars and has its own subsidiaries for batteries and chips.

    This position pays off, especially in the current shortage. The Company in which Warren Buffett, among others, has invested, impresses above all with its growth. In 2021, BYD sold 232% more electric vehicles and hybrids than in the previous year. Tesla's growth was only around 87%. But while Tesla only sells electric models, BYD also offers hybrid models, which are very popular in China. Consequently, BYD also has more models than Tesla.

    BYD's stock crashed recently despite the rich growth, losing more than 10% within five days. However, if you look at the long-term trend, you can still see the stock in a positive trend over a period of several years. At the current level, it will be decided where the journey will lead. However, with its own chip production and the most important sales market on its doorstep, BYD is ideally positioned to gain market share in the future.

    BrainChip: Financial giants invest in AI chips

    The innovative chip developer BrainChip is not yet concerned with market share. Instead, the revolutionary technology must first be launched on the market. But from the market's point of view, it is evident that this will succeed: the share price has risen rapidly in recent weeks and demonstrated great relative strength even in the midst of the correction. BrainChip designs semiconductors based on the human brain. The chips are self-learning, self-sufficient and require hardly any energy. The Company, therefore, wants to score points above all in autonomous driving and powerfully support the vision of the mobility turnaround.

    Looking at the list of BrainChip's 20 largest shareholders shows that BrainChip is not alone in this vision. They include HSBC Australia, Citicorp, Merril Lynch Australia, BNP Paribas, JP Morgan, UBS, LDA Capital - even ex-BrainChip CEO Louis Dinardo remains loyal to his former Company. After the correction, BrainChip could be a promising bet on the future of chip technology. The current CFO, Ken Scarince, will present his Company and answer questions at no cost at the online International Investment Forum on February 17. Growth investors should make a note of this date and all other presentations by the top-class panel.

    Daimler needs a European chip solution

    BrainChip's chips are also likely to be of interest to traditional automotive producers, such as Daimler. After all, it makes sense to evaluate the potential of the future in good time. Looking at the valuation of Daimler's stock, the market has moved sideways over the past three months, but the share is still in solid long-term waters. Fundamentally, Daimler also came through the second crisis year 2021 well. Both the sales of all cars and the growth in e-cars can be seen at Daimler. On top of that, the Company offers a dividend of almost 5%. However, Daimler also needs to keep its eye on the ball regarding chips and other key upstream products to remain competitive. Both current supply and access to new chip generations are crucial for a company like Daimler.


    Industrial companies like Daimler are likely to benefit most from the new European semiconductor offensive. But it will be some time before the strategy bears fruit. It also remains questionable whether the Europeans will be able to secure technological leadership so quickly. Innovative disruptors like BrainChip, therefore, remain attractive.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read